maliqun61 schreef op 11 januari 2019 08:20:
Uit HAEUK news dd 23 december 2018
C1 INH SUPPLY
Since the extreme shortages of C1-INH throughout the past few months, supplies are slowly starting to build up, but CSL Behring stress that in order to ensure everyone gets supplied, they are sticking to their policy of delivering smaller amounts fortnightly, instead of larger amounts less frequently.
Shire can supply existing patients with Cinryze but have no extra supply.
CSL Behring hope that a couple more months using this strict supply control will be sufficient to replenish their supplies and deliveries can then start returning to normal.
Sadly, at the present time UK plasma is not used for fractionation because of the risk of contamination with variant CJD. Currently there is no reliable way of removing ‘prions’ which are the contaminating proteins, so plasma used for fractionation is sourced from countries where there has never been any cases of ‘mad cow disease’.
Despite all the testing and incredibly high standards maintained by the plasma industry, there are still occasions when problems occur and this will result in an entire fractionation run being destroyed. This can then create shortages which may be only local or can be global.
TREATMENTS IN SCOTLAND AND WALES
We have also had success over the Summer with the devolved governments; Scotland accepting an application for Ruconest to be available to Scottish patients and Wales allowing Icatibant and Ruconest to be available. This means they are automatically funded by NHS Scotland/NHS Wales and are freely available for prescription.
www.haeuk.org/wp-content/uploads/2018...